Hironic Co

Hironic Co Gross Margin

The Gross Margin of Hironic Co (149980.KQ) as of Nov 5, 2026 is 58.93 %. In the previous year, Gross Margin was 38.68 % — a change of 52.35% (higher).

Gross Margin

58.93 %

YoY

52.35%

Last updated:

Gross Margin of Hironic Co is 2025 58.93 % . Gross Margin of Hironic Co was 2024 38.68 % . It decreases by 52.35% higher compared to the previous year.

Hironic Co's gross margin stands at 58.9%, down from 60.8% several years earlier.

The Hironic Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
58.66 KRW
Jan 1, 2019
59.62 KRW
Jan 1, 2020
62.11 KRW
Jan 1, 2021
60.75 KRW
Jan 1, 2022
53.95 KRW
Jan 1, 2023
56.90 KRW
Jan 1, 2024
38.68 KRW
Jan 1, 2025
58.93 KRW
The Hironic Co Gross Margin history
YEARGross MarginYoY
58.93 %+52.35%
38.68 %-32.02%
56.90 %+5.46%
53.95 %-11.19%
60.75 %-2.18%
62.11 %+4.18%
59.62 %+1.63%
58.66 %-10.44%
65.49 %+2.01%
64.20 %-4.36%
67.13 %+0.32%
66.91 %+10,654.21%
0.62 %+13.27%
0.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hironic Co Stock analysis

What does Hironic Co do? Hironic Co., Ltd. generates revenue through the manufacture and sale of medical equipment for skin and obesity care. The company's product lineup includes MIXEL, designed for treating skin lesions and melasma while enhancing skin texture and tone; MIPL, which addresses pigmentation, wrinkles, vascular issues, acne, and hair removal; MIDEPI, a dedicated hair removal device; DOUBLO, used for skin tightening, rejuvenation, and non-invasive facial and eyebrow lifting; MICOOL, for natural fat cell destruction; and New Midas, targeting body contouring and facial lifting. These products are sold to medical facilities and clinics specializing in dermatology and cosmetic treatments, with a focus on skin and obesity care segments. The company's revenue streams are derived from direct sales of its branded medical devices to healthcare providers. MIXEL and MIPL cater to dermatological treatments, while MIDEPI and MICOOL serve aesthetic and body contouring markets. DOUBLO and New Midas are positioned for non-invasive cosmetic procedures, appealing to clinics seeking advanced solutions for skin tightening and facial rejuvenation. Hironic's product portfolio targets both skin treatment and obesity care, aligning with the growing demand for specialized medical equipment in these sectors. Hironic Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hironic Co stock

Gross Margin of Hironic Co is 58.93 % in 2025.

Gross Margin of Hironic Co changed from 38.68 % to 58.93 %, representing a 52.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Hironic Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Hironic Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Hironic Co

All Key Metrics — Hironic Co